Treatment Advances

October 04, 2024

What are natural killer cells? Why do they stop killing chronic lymphocytic leukemia (CLL) cells? What can potentially fix this?

July 31, 2024

Allison Winter, MD, presented data about how the CAR T-cell therapy liso-cel helped CLL patients who have experienced Richter transformation.

July 07, 2024

Venetoclax (Venclexta) may stop working. Learn about resistance, treatment options after relapse, and promising new research for chronic lymphocytic leukemia.

June 24, 2024

Explore Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia (CLL). Learn about treatment options, patient outcomes, and how it improves quality of life.

May 31, 2024

Sonrotoclax is a second-generation BCL-2 inhibitor created by BeiGene. CLL patients may be familiar with the first-generation BCL-2 inhibitor venetoclax.

May 09, 2024

Help for the patient with CLL choosing between acalabrutinib and zanubrutinib: Learn current decision-making factors

March 15, 2024

The first-ever CAR T-cell therapy for CLL (liso-cel (Breyanzi)) is now FDA approved.

December 12, 2023

Dr. Wang from COH found links between issues with the MGA gene causing CLL cells to undergo Richter’s transformation.

December 06, 2023

The non-covalent BTK inhibitor pirtobrutinib received FDA approval for the treatment of CLL patients who have received at least two prior lines of therapy...

November 15, 2023

CLL researchers found insight into one of the main causes of high-risk CLL cells multiplying quickly and a new medicine that helped stop CLL cell progression.